FDA Recalls EPINEPHrine IV Bags for Unvalidated Sterilization Processes
Central Admixture Pharmacy Services is recalling 340 bags of epinephrine IV solution due to inadequate validation of sterilization procedures, creating a potential contamination risk.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable drug involving unvalidated sterilization processes that poses a genuine contamination risk. No illnesses or injuries have been reported, so per the rubric this qualifies as a risk-of-harm product without reported injury, resulting in a High (3) severity score.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling EPINEPHrine 2 mg in dextrose 5% solution, supplied in 250 mL IV bags at a concentration of 8 mcg/mL. The recall affects 340 bags with lot number 36-260049 and an expiration date of October 3, 2023. The product was distributed nationwide in the USA.
The recall was initiated because the sanitization cycles used in manufacturing the IV bags were not adequately validated to provide assurance of sterility. This means the sterilization processes cannot be confirmed to have effectively removed microbial contamination.
Hospitals and healthcare facilities that received these IV bags should immediately discontinue use and return the product to the manufacturer. If doses have already been administered, patients should consult their healthcare provider. Healthcare providers should monitor patients for signs of infection.
The recalled product
- Product
- EPINEPHrine, 2 mg added to dextrose 5% 250mL, Concentration = 8 mcg/mL, IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-6030-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Intravenous Injection
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 36-260049
- Exp 10/3/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27